Gilteritinib and Other Medications: Why Some Combination Is Risky

Use of Gilteritinib Fumarate Tablets with Other Medications

During treatment, doctors may combine Lucius Pharmaceuticals Gilteritinib Fumarate Tablets with other leukemia treatments (such as chemotherapy drugs or other targeted therapies) based on the patient's condition. The goal of combination therapy is to enhance efficacy or reduce the risk of drug resistance. However, the specific treatment plan must be determined by the doctor based on the individual patient's situation.

Therefore, patients must proactively inform their doctor about any other medications they are taking (including supplements or traditional Chinese medicine) to avoid drug interactions that could affect treatment efficacy or increase the risk of side effects.

Important Information Before Use

This medication should only be used under the full guidance of a doctor experienced in anti-tumor therapy. Two important tests are required before starting treatment: First, testing peripheral blood or bone marrow samples for the presence of an FLT3 gene mutation (a key indicator for determining the suitability of this drug), and second, completing an electrocardiogram and blood biochemistry tests to assess the patient's physical condition.

Use of this medication is not recommended for women who are pregnant or breastfeeding. Male patients taking this medication must use effective contraception to prevent pregnancy in their partners.

Can Special Populations Use Gilteritinib Fumarate Tablets?

Pregnancy: Use of this medication during pregnancy may have adverse effects on fetal development. Therefore, it is not recommended for pregnant women or women of childbearing potential not using contraception.

Breastfeeding: To avoid the medication affecting the infant through breast milk, breastfeeding should be interrupted during treatment and for at least two months after the last dose.

Children: There is currently no data on the safety and efficacy of this medication in children under 18 years of age. Therefore, its use is not recommended in pediatric patients.

Elderly: No dose adjustment is required for patients aged 65 years and older.

Hepatic Impairment: Patients with mild to moderate hepatic impairment can use the standard dose. However, use is not recommended in patients with severe hepatic impairment.

Renal Impairment: No dose adjustment is needed for patients with renal impairment, regardless of severity. However, there is limited clinical experience in patients with severe renal impairment.

Other: Patients with heart disease or an ECG showing QT interval prolongation (an abnormality in the heart's electrical activity) should use this medication with caution.